[The polypill: optimal strategy for reduction of cardiovascular disease]

H M Nathoe; P A F M Doevendans

[The polypill: optimal strategy for reduction of cardiovascular disease]

Ned Tijdschr Geneeskd. 2005 Jul 30;149(31):1740.

[Article in Dutch]

Authors

H M Nathoe¹, P A F M Doevendans

Affiliation

¹ Universitair Medisch Centrum Utrecht, afd. Cardiologie, Postbus 85.500, 3508 GA Utrecht.

PMID: 16114290

Abstract

Treating all persons above 55 years of age with a polypill for primary and secondary cardiovascular-disease prevention may reduce cardiovascular events by more than 80%. This strategy is expected to be cost-effective and the associated risk of side effects is estimated to be low.

Publication types

English Abstract

MeSH terms

Antihypertensive Agents / administration & dosage*
Aspirin / administration & dosage*
Cardiovascular Diseases / mortality
Cardiovascular Diseases / prevention & control*
Cost-Benefit Analysis
Drug Combinations
Female
Folic Acid / administration & dosage*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
Male
Middle Aged
Platelet Aggregation Inhibitors / administration & dosage*
Primary Prevention

Substances

Antihypertensive Agents
Drug Combinations
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Platelet Aggregation Inhibitors
Folic Acid
Aspirin